Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 149

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 4
Chunk 149
---
 submitted an ANDA to the FDA seeking authorization from the FDA to manufacture, use or sell a generic version of EXPAREL in the U.S. Each letter alleged that EXPAREL patents listed in the FDA’s Orange Book are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed products described in these ANDA submissions.

We are currently assessing these notification letters and have 45 days from the applicable date of receipt to commence patent infringement lawsuits against these generic challengers if we believe they are infringing our intellectual property. In the event that we file one or more patent infringement lawsuit(s), the FDA would enter a 30-month stay of final approval of the ANDA(s). We intend to vigorously defend our intellectual property rights relating to EXPAREL. We are unable to predict the outcome of these matters at this time.

For more information on these litigations and other legal proceedings we are involved in, see Note 16, Commitments and Contingencies, to our condensed consolidated financial statements included herein.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  59

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Registrant

The following table provides information on our share repurchases during the quarter ended September 30, 2025:

Issuer Purchases of Equity SecuritiesPeriodTotal Numberof Shares PurchasedAverage PricePaid Per Share (1)Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)July 1, 2025 – July 31, 2025—$— —$249,999,997 August 1, 2025 – August 31, 20251,762,524$25.11 1,762,524$205,734,498 September 1, 2025 – September 30, 2025213,993$26.80 213,993$199,998,530 Total1,976,517$25.30 1,976,517$199,998,530 

(1) The average price paid per share excludes less than $0.1 million of broker fees and $0.3 million of excise tax incurred